Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

New Tuberculostatic Agents Targeting Nucleic Acid Biosynthesis: Drug Design using QSAR Approaches

Bueno, Renata V. [1] ; Braga, Rodolpho C. [2, 1] ; Segretti, Natanael D. [3] ; Ferreira, Elizabeth I. [3] ; Trossini, Gustavo H. G. [3] ; Andrade, Carolina H. [1]
Total Authors: 6
[1] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Design, Setor Univ, BR-74605220 Goiania, Go - Brazil
[2] Univ Fed Goias, Inst Quim, BR-74001970 Goiania, Go - Brazil
[3] Univ Sao Paulo, Fac Ciencias Farmaceut, LAPEN, BR-05508900 Sao Paulo - Brazil
Total Affiliations: 3
Document type: Journal article
Source: CURRENT PHARMACEUTICAL DESIGN; v. 20, n. 27, p. 4474-4485, 2014.
Web of Science Citations: 14

Worldwide, tuberculosis (TB) is the leading cause of death among curable infectious diseases. The emergence of multidrug resistant (MDR) and extensively drug resistant (XDR) TB is a growing global health concern and there is an urgent need for new anti-TB drugs. Enzymes involved in DNA and ATP biosynthesis are potential targets for tuberculostatic drug design, since these enzymes are essential for Mycobacterium tuberculosis growth. This review presents the current progress and applications of structure-activity relationship analysis for the discovery of innovative tuberculostatic agents as inhibitors of ribonucleotide reductase, DNA gyrase, ATP synthase, and thymidylate kinase enzymes, highlighting present challenges and new opportunities in TB drug design. (AU)

FAPESP's process: 11/11499-0 - Bioisosterism in the design of new antichagasic agents: integration of computational and experimental strategies
Grantee:Gustavo Henrique Goulart Trossini
Support Opportunities: Regular Research Grants